

**Provisional Draft Agenda**  
**69<sup>th</sup> meeting of the Member State Committee**  
(Web conference)

**22-23 April 2020**  
ECHA Conference Centre

**22 April: starts at 10:30 am (Helsinki time, CET+1)**  
**23 April: ends at 16:00 (Helsinki time, CET+1)**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

MSC/A/069/2020  
***For adoption***

**Item 3 – Declaration of specific interests to items on the Agenda**

**Item 4 – Administrative issues**

- Alternative option to the identification and appointment of rapporteurs  
***For decision***
- Update to the MSC Rules of procedures  
***For discussion and endorsement***
- Outlook for MSC-70, MSC-70bis and MSC-71  
***For information***

**Item 5 – Minutes of the MSC-68**

- Final/Draft minutes of MSC-68  
MSC/M/68/2020  
***For information/adoption***

**Item 6 – Substance evaluation**

***Closed session for 6.3***

1. Written procedure report on seeking agreement on draft decisions on substance evaluation  
***For information***
2. Introduction to and preliminary discussion on draft decisions on substance evaluation when amendments were proposed by MS-CA's/ECHA (*Session 1, open session*):

***For discussion followed by agreement seeking under 6.3:***

| <b>Case</b>                  | <b>Substance</b>  | <b>EC N:o</b> |
|------------------------------|---|---------------|
| SEV-DE-001/2018              | 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione            | 258-904-8     |
| SEV-DE-002/2018              | 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione, zinc salt | 262-872-0     |
| SEV-SE-011/2018 <sup>1</sup> | Butanone  | 201-159-0     |

***For discussion***

**3. Seeking agreement on draft decisions when amendments were proposed by MS-CA's/ECHA (*Session 2, closed*)**

Cases as listed above under 6.2 and any cases stopped in written procedure

***For agreement***

**4. General topics**

- 1) Status report on on-going substance evaluation work

***For information***

**Item 7 – Dossier evaluation**

***Closed session for 7.3 and partly for 7.4***

**1. Written procedure report on seeking agreement on draft decisions on dossier evaluation**

***For information***

**2. Introduction to and preliminary discussion on draft decisions on compliance checks and testing proposals when amendments were proposed by MS-CA's (*Session 1, open session*)**

***For discussion followed by agreement seeking under 7.3:***

**Compliance checks**

| <b>MSC code</b>           | <b>Substance name</b>                  | <b>EC/List No.</b> |
|---------------------------|--|--------------------|
| CCH-004/2020 <sup>1</sup> | 3a,4,7,7a-tetrahydro-4,7-methanoindene | 201-052-9          |
| CCH-031/2020 <sup>1</sup> | Barium dodecairon nonadecaoxide        | 234-974-5          |

**Testing proposal examinations**

| <b>MSC code</b>           | <b>Substance name</b>                  | <b>EC/List No.</b> |
|---------------------------|--|--------------------|
| TPE-001/2020 <sup>1</sup> | 3a,4,7,7a-tetrahydro-4,7-methanoindene | 201-052-9          |

***For discussion***

**3. Seeking agreement on draft decisions on compliance checks and testing proposal examinations when amendments were proposed by MS-CA's (*Session 2, closed*)**

Cases as listed above under 7.2 and any cases stopped in written procedure

***For agreement***

**4. General topics**

- 1) Status report on on-going dossier evaluation work

***For information***

**Item 8 – SVHC identification**

<sup>1</sup> Case to be removed from the agenda if agreed in MSC written procedure in advance of the meeting.

Not relevant for this meeting

***[For information]***

**Item 9 – ECHA’s recommendations of priority substances to be included in Annex XIV and opinion of MSC**

Not relevant for this meeting

***[For information]***

**Item 10 – Opinion of MSC on ECHA’s draft update of the Community Rolling Action Plan (CoRAP 2020-2022)**

- Timeline for next CoRAP update and rapporteur appointment

***For discussion***

**Item 11 – Any other business**

1. Update on appeals and court cases of relevance to MSC

*(Partly closed session)*

***For information***

2. Suggestions from members

***For information***

**Item 12 – Adoption of main conclusions and action points**

- Table with conclusions and action points from MSC-69

***For adoption***